HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1.
about
Structural Evidence for Effectiveness of Darunavir and Two Related Antiviral Inhibitors against HIV-2 ProteaseTransmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg databasePolymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 proteaseHIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in SenegalPolymorphisms of HIV-2 integrase and selection of resistance to raltegravirRevealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.A modular system to evaluate the efficacy of protease inhibitors against HIV-2Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitorsIn vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavirIn vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including DarunavirEmergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West AfricaComplex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.Antiretroviral drug resistance in human immunodeficiency virus type 2.Special aspects of the treatment of HIV-2-infected patients.HIV-2 Protease resistance defined in yeast cells.GRL-079, a novel P2-Tp-THF-C5-alkylamine- and P2' -Abt-containing HIV-1 protease inhibitor, is extremely potent against multi-drug-resistant HIV-1 variants including HIVDRVRp51 and has a high genetic barrier against the emergence of resistant varian
P2860
Q27652399-5423FEF6-DBC6-49AF-BB44-66F46E627660Q33321434-D8635FCD-911B-43AD-973B-EF509A9518EFQ33593237-AEDB5F0C-803C-46A4-B75E-7388FB567EDAQ33650307-11080A01-748A-4FAD-82DA-6279ED7F6066Q34080828-4F811DD9-6D8C-4F6A-A229-B0C70214ED11Q34426605-929FAE24-0906-416E-8C06-4E2190E8A328Q34440391-67AABCE4-62D2-40C2-8DDC-81FCF209A8C6Q35206272-FB06ABCE-1D89-4BB8-A206-5B6171FD0C70Q35445731-A45AEE57-B3A3-43D6-B39F-CE2147D9D85BQ35636029-32940BB1-3EFD-4C58-A7F9-500193B142C5Q36094944-5BD8971A-7CFF-4358-95E6-63070FA6B186Q36538702-AAEC55BE-F246-4F6F-8533-9B7555476E66Q36736848-C2E5B914-669E-472C-9D83-0349A6F244B0Q36897863-BFEF9694-BDB7-4A15-B747-90AD5554C88EQ37026564-FBDA9038-D15B-42C0-81D5-031FE1755797Q37083896-1B894858-5A5C-49F5-8104-CA4E2395B44BQ37496287-E82C1AD3-CE35-4017-99CC-0303D9B165D9Q37979706-B236BB9B-6911-48D4-9C60-7BBA2476B3C1Q43249256-F6321CBD-9B9B-4BED-9F82-903E9551B4F1Q49792045-53C797A6-C036-4EAB-B721-347E80FF0A98
P2860
HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
HIV-2 protease sequences of su ...... inhibitor resistance in HIV-1.
@en
HIV-2 protease sequences of su ...... inhibitor resistance in HIV-1.
@nl
type
label
HIV-2 protease sequences of su ...... inhibitor resistance in HIV-1.
@en
HIV-2 protease sequences of su ...... inhibitor resistance in HIV-1.
@nl
prefLabel
HIV-2 protease sequences of su ...... inhibitor resistance in HIV-1.
@en
HIV-2 protease sequences of su ...... inhibitor resistance in HIV-1.
@nl
P2093
P50
P1433
P1476
HIV-2 protease sequences of su ...... inhibitor resistance in HIV-1
@en
P2093
Clement Zeh
Danuta Pieniazek
John N Nkengasong
Liliana Odama
Mark Rayfield
Simon M Agwale
Stefan Z Wiktor
P304
P356
10.1097/00002030-200402200-00016
P407
P577
2004-02-01T00:00:00Z